REFERENCES
1. Iung B, Delgado V, Rosenhek R, et al. EORP VHD II Investigators. Contemporary presentation and management of valvular heart disease: the Eurobservational research programme valvular heart disease II survey. Circulation 2019;140:1156-69.
2. Stewart B, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease fn1fn1. J Am Coll Cardiol 1997;29:630-4.
3. Yan AT, Koh M, Chan KK, et al. Association between cardiovascular risk factors and aortic stenosis: the CANHEART aortic stenosis study. J Am Coll Cardiol 2017;69:1523-32.
5. Auffret V, Lefevre T, Van Belle E, et al. FRANCE TAVI Investigators. Temporal trends in transcatheter aortic valve replacement in France: France 2 to France TAVI. J Am Coll Cardiol 2017;70:42-55.
6. Makkar RR, Fontana GP, Jilaihawi H, et al. PARTNER Trial Investigators. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012;366:1696-704.
7. Kodali SK, Williams MR, Smith CR, et al. PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012;366:1686-95.
8. Reardon MJ, Van Mieghem NM, Popma JJ, et al. SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017;376:1321-31.
9. Leon MB, Smith CR, Mack MJ, et al. PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-20.
10. Mack MJ, Leon MB, Thourani VH, et al. PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.
11. Popma JJ, Deeb GM, Yakubov SJ, et al. Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706-15.
12. Saia F, Palmerini T, Compagnone M, et al. Coronary artery disease and reasonably incomplete coronary revascularization in high-risk patients undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2020;95:19-27.
13. Witberg G, Regev E, Chen S, et al. The prognostic effects of coronary disease severity and completeness of revascularization on mortality in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:1428-35.
14. Kleczynski P, Dziewierz A, Bagienski M, et al. Impact of coronary artery disease burden on 12-month mortality of patients after transcatheter aortic valve implantation. J Interv Cardiol 2016;29:375-81.
15. Kotronias RA, Kwok CS, George S, et al. Transcatheter aortic valve implantation with or without percutaneous coronary artery revascularization strategy: a systematic review and meta-analysis. J Am Heart Assoc 2017;6:e005960.
16. Witberg G, Zusman O, Codner P, Assali A, Kornowski R. Impact of coronary artery revascularization completeness on outcomes of patients with coronary artery disease undergoing transcatheter aortic valve replacement: a meta-analysis of studies using the residual SYNTAX score (Synergy Between PCI With Taxus and Cardiac Surgery). Circ Cardiovasc Interv 2018;11:e006000.
17. D'Ascenzo F, Verardi R, Visconti M, et al. Independent impact of extent of coronary artery disease and percutaneous revascularisation on 30-day and one-year mortality after TAVI: a meta-analysis of adjusted observational results. EuroIntervention 2018;14:e1169-77.
18. Tjang YS, van Hees Y, Körfer R, Grobbee DE, van der Heijden GJ. Predictors of mortality after aortic valve replacement. Eur J Cardiothorac Surg 2007;32:469-74.
19. Fujita B, Ensminger S, Bauer T, et al. GARY Executive Board. Trends in practice and outcomes from 2011 to 2015 for surgical aortic valve replacement: an update from the German Aortic Valve Registry on 42776 patients. Eur J Cardiothorac Surg 2018;53:552-9.
20. Vahanian A, Beyersdorf F, Praz F, et al. ESC/EACTS Scientific Document Group, ESC Scientific Document Group. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J ;2021:ehab395.
21. Otto CM, Nishimura RA, Bonow RO, et al. Writing Committee Members. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol 2021;77:450-500.
22. Khawaja MZ, Wang D, Pocock S, Redwood SR, Thomas MR. The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. Trials 2014;15:300.
23. Patterson T, Clayton T, Dodd M, et al. ACTIVATION Trial Investigators. ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): a randomized clinical trial. JACC Cardiovasc Interv 2021;14:1965-74.
24. Søndergaard L, Popma JJ, Reardon MJ, et al. SURTAVI Trial Investigators. Comparison of a complete percutaneous versus surgical approach to aortic valve replacement and revascularization in patients at intermediate surgical risk: results from the randomized SURTAVI trial. Circulation 2019; doi: 10.1161/CIRCULATIONAHA.118.039564.
25. Barbanti M, Buccheri S, Capodanno D, et al. OBSERVANT Research Group. Transcatheter or surgical treatment of severe aortic stenosis and coronary artery disease: a comparative analysis from the Italian OBSERVANT study. Int J Cardiol 2018;270:102-6.
26. Kotronias RA, Bray JH, Scarsini R, et al. Transcatheter aortic valve replacement and percutaneous coronary intervention versus surgical aortic valve replacement and coronary artery bypass grafting in patients with severe aortic stenosis and concomitant coronary artery disease: a systematic review and meta-analysis. Catheter Cardiovasc Interv 2020;96:1113-25.
27. Barbato E, Toth GG, Johnson NP, et al. A prospective natural history study of coronary atherosclerosis using fractional flow reserve. J Am Coll Cardiol 2016;68:2247-55.
28. van Nunen LX, Zimmermann FM, Tonino PAL, et al. Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet 2015;386:1853-60.
29. Fearon WF, Nishi T, De Bruyne B, et al. FAME 2 Trial Investigators. Clinical outcomes and cost-effectiveness of fractional flow reserve-guided percutaneous coronary intervention in patients with stable coronary artery disease: three-year follow-up of the FAME 2 trial (fractional flow reserve versus angiography for multivessel evaluation). Circulation 2018;137:480-7.
30. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407-77.
31. Rajappan K, Rimoldi OE, Dutka DP, et al. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 2002;105:470-6.
32. Eberli FR, Ritter M, Schwitter J, et al. Coronary reserve in patients with aortic valve disease before and after successful aortic valve replacement. Eur Heart J 1991;12:127-38.
33. Stoller M, Gloekler S, Zbinden R, et al. Left ventricular afterload reduction by transcatheter aortic valve implantation in severe aortic stenosis and its prompt effects on comprehensive coronary haemodynamics. EuroIntervention 2018;14:166-73.
34. Scarsini R, De Maria GL, Di Gioia G, et al. The influence of aortic valve obstruction on the hyperemic intracoronary physiology: difference between resting Pd/Pa and FFR in aortic stenosis. J Cardiovasc Transl Res 2019;12:539-50.
35. Pesarini G, Scarsini R, Zivelonghi C, et al. Functional assessment of coronary artery disease in patients undergoing transcatheter aortic valve implantation: influence of pressure overload on the evaluation of lesions severity. Circ Cardiovasc Interv 2016;9:e004088.
36. Lunardi M, Scarsini R, Venturi G, et al. Physiological versus angiographic guidance for myocardial revascularization in patients undergoing transcatheter aortic valve implantation. J Am Heart Assoc 2019;8:e012618.
37. Ahmad Y, Götberg M, Cook C, et al. Coronary hemodynamics in patients with severe aortic stenosis and coronary artery disease undergoing transcatheter aortic valve replacement: implications for clinical indices of coronary stenosis severity. JACC Cardiovasc Interv 2018;11:2019-31.
38. Yamanaka F, Shishido K, Ochiai T, et al. Instantaneous wave-free ratio for the assessment of intermediate coronary artery stenosis in patients with severe aortic valve stenosis: comparison with myocardial perfusion scintigraphy. JACC Cardiovasc Interv 2018;11:2032-40.
39. Scarsini R, Cantone R, Venturi G, et al. Correlation between intracoronary physiology and myocardial perfusion imaging in patients with severe aortic stenosis. Int J Cardiol 2019;292:162-5.
40. Scarsini R, Pesarini G, Lunardi M, et al. Observations from a real-time, iFR-FFR "hybrid approach" in patients with severe aortic stenosis and coronary artery disease undergoing TAVI. Cardiovasc Revasc Med 2018;19:355-9.
41. Goel SS, Agarwal S, Tuzcu EM, et al. Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation 2012;125:1005-13.
42. Faroux L, Campelo-Parada F, Munoz-Garcia E, et al. Procedural characteristics and late outcomes of percutaneous coronary intervention in the workup pre-TAVR. JACC Cardiovasc Interv 2020;13:2601-13.
43. van Rosendael PJ, van der Kley F, Kamperidis V, et al. Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation. Am J Cardiol 2015;115:1726-32.
44. Venturi G, Pighi M, Pesarini G, et al. Contrast-induced acute kidney injury in patients undergoing TAVI compared with coronary interventions. J Am Heart Assoc 2020;9:e017194.
45. Barbanti M, Todaro D, Costa G, et al. Optimized screening of coronary artery disease with invasive coronary angiography and ad hoc percutaneous coronary intervention during transcatheter aortic valve replacement. Circ Cardiovasc Interv 2017;10:e005234.
46. Ben-Dor I, Maluenda G, Looser PM, et al. Outcomes of concomitant percutaneous coronary intervention and balloon aortic valvuloplasty. Catheter Cardiovasc Interv 2013;82:E835-41.
47. Daniec M, Sorysz D, Dziewierz A, et al. In-hospital and long-term outcomes of percutaneous balloon aortic valvuloplasty with concomitant percutaneous coronary intervention in patients with severe aortic stenosis. J Interv Cardiol 2018;31:60-7.
48. Singh V, Mendirichaga R, Inglessis-Azuaje I, Palacios IF, O'Neill WW. The role of impella for hemodynamic support in patients with aortic stenosis. Curr Treat Options Cardiovasc Med 2018;20:44.
49. Diaz Quintero L, Gajo E, Guerrero M, Feldman T, Levisay J. Balloon aortic valvuloplasty followed by impella®-assisted left main coronary artery percutaneous coronary intervention in patients with severe aortic stenosis as a bridge to transcatheter aortic valve replacement. Cardiovasc Revasc Med 2021;22:16-21.
50. Nai Fovino L, Scotti A, Massussi M, et al. Incidence and feasibility of coronary access after transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2020;96:E535-41.
51. Yudi MB, Sharma SK, Tang GHL, Kini A. Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. J Am Coll Cardiol 2018;71:1360-78.
52. Ribeiro HB, Webb JG, Makkar RR, et al. Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation: insights from a large multicenter registry. J Am Coll Cardiol 2013;62:1552-62.
53. Barbanti M, Costa G, Picci A, et al. Coronary cannulation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC Cardiovasc Interv 2020;13:2542-55.
54. Ochiai T, Chakravarty T, Yoon SH, et al. Coronary access after TAVR. JACC Cardiovasc Interv 2020;13:693-705.
55. Katsanos S, Debonnaire P, van der Kley F, et al. Position of edwards SAPIEN transcatheter valve in the aortic root in relation with the coronary ostia: implications for percutaneous coronary interventions. Catheter Cardiovasc Interv 2015;85:480-7.
56. Abdelghani M, Landt M, Traboulsi H, Becker B, Richardt G. Coronary access after TAVR with a self-expanding bioprosthesis: insights from computed tomography. JACC Cardiovasc Interv 2020;13:709-22.
57. Rogers T, Greenspun BC, Weissman G, et al. Feasibility of coronary access and aortic valve reintervention in low-risk TAVR patients. JACC Cardiovasc Interv 2020;13:726-35.
58. Tang GHL, Zaid S, Fuchs A, et al. Alignment of transcatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orientation and coronary artery overlap. JACC Cardiovasc Interv 2020;13:1030-42.
59. Tagliari AP, Vicentini L, Zimmermann JM, et al. Transcatheter aortic valve neo-commissure alignment with the Portico system. EuroIntervention 2021;17:e152-5.
60. Bieliauskas G, Wong I, Bajoras V, et al. Patient-specific implantation technique to obtain neo-commissural alignment with self-expanding transcatheter aortic valves. JACC Cardiovasc Interv 2021;14:2097-108.
61. Tarantini G, Nai Fovino L, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv 2020;13:e008972.
62. Khan M, Senguttuvan NB, Krishnamoorthy P, et al. Coronary angiography and percutaneous coronary intervention after transcatheter aortic valve replacement with medtronic self-expanding prosthesis: insights from correlations with computer tomography. Int J Cardiol 2020;317:18-24.
63. Bharadwaj AS, Bhatheja S, Sharma SK, Kini AS. Utility of the guideliner catheter for percutaneous coronary interventions in patients with prior transcatheter aortic valve replacement. Catheter Cardiovasc Interv 2018;91:271-6.
64. Ochiai T, Yoon SH, Flint N, et al. Timing and outcomes of percutaneous coronary intervention in patients who underwent transcatheter aortic valve implantation. Am J Cardiol 2020;125:1361-8.
65. Stefanini GG, Cerrato E, Pivato CA, et al. REVIVAL Investigators. Unplanned percutaneous coronary revascularization after TAVR: a multicenter international registry. JACC Cardiovasc Interv 2021;14:198-207.
66. Faroux L, Lhermusier T, Vincent F, et al. ST-segment elevation myocardial infarction following transcatheter aortic valve replacement. J Am Coll Cardiol 2021;77:2187-99.
67. Kim WK, Pellegrini C, Ludwig S, et al. Feasibility of coronary access in patients with acute coronary syndrome and previous TAVR. JACC Cardiovasc Interv 2021;14:1578-90.
68. Nai Fovino L, Scotti A, Massussi M, et al. Coronary angiography after transcatheter aortic valve replacement (TAVR) to evaluate the risk of coronary access impairment after TAVR-in-TAVR. J Am Heart Assoc 2020;9:e016446.
69. Baumbach H, Schairer ER, Wachter K, et al. Transcatheter aortic valve replacement- management of patients with significant coronary artery disease undergoing aortic valve interventions: surgical compared to catheter-based approaches in hybrid procedures. BMC Cardiovasc Disord 2019;19:108.
70. Ahad S, Wachter K, Rustenbach C, et al. Concomitant therapy: off-pump coronary revascularization and transcatheter aortic valve implantation. Interact Cardiovasc Thorac Surg 2017;25:12-7.
71. Mayr B, Firschke C, Erlebach M, et al. Transcatheter aortic valve implantation and off-pump coronary artery bypass surgery: an effective hybrid procedure in selected patients. Interact Cardiovasc Thorac Surg 2018;27:102-7.
72. Pirelli L, Patel NC, Scheinerman JS, et al. Hybrid minimally invasive approach for combined obstructive coronary artery disease and severe aortic stenosis. Innovations (Phila) 2020;15:131-7.
73. Santana O, Funk M, Zamora C, Escolar E, Lamas GA, Lamelas J. Staged percutaneous coronary intervention and minimally invasive valve surgery: results of a hybrid approach to concomitant coronary and valvular disease. J Thorac Cardiovasc Surg 2012;144:634-9.
74. Santana O, Xydas S, Williams RF, et al. Outcomes of a hybrid approach of percutaneous coronary intervention followed by minimally invasive aortic valve replacement. J Thorac Dis 2017;9:S569-74.
75. Brinster DR, Byrne M, Rogers CD, et al. Effectiveness of same day percutaneous coronary intervention followed by minimally invasive aortic valve replacement for aortic stenosis and moderate coronary disease ("hybrid approach"). Am J Cardiol 2006;98:1501-3.
76. George I, Nazif TM, Kalesan B, et al. Feasibility and early safety of single-stage hybrid coronary intervention and valvular cardiac surgery. Ann Thorac Surg 2015;99:2032-7.
